Contribute Try STAT+ Today

Amid ongoing debate over taxpayer dollars used to generate medicines, a new analysis contends that public investments contributed up to five times more than what Johnson & Johnson (JNJ) spent to develop Sirturo, its groundbreaking drug for tuberculosis.

Public sector funds worth an estimated $455 million to $747 million were used to pay for clinical trials, tax credits, administration of a tax-deductible donation program, and a redeemable regulatory voucher, according to the analysis, published in PLoS One. By comparison, the health care giant was estimated to have invested anywhere from $90 million to $240 million on getting the tuberculosis drug to market.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED

What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.
  • May one also observe that including the cost of “the redeemable regulatory voucher” is problematic? If JNJ ‘earned’ the voucher, then it’s a benefit that was publicly given. (And it only speeds up review, I believe, and would have no effect of User / PDUFA fees.) If they purchased the voucher, then it’s a cost.
    A worthy analysis but as was written above, one with “limitations.”

Comments are closed.